<DOC>
	<DOCNO>NCT03103412</DOCNO>
	<brief_summary>This study design evaluate safety , tolerability , pharmacokinetics ( PK ) single-dose TD-3504 single dose 15N2-tofacitinib healthy subject subject UC . The relative bioavailability tofacitinib release TD-3504 compare co-administered oral heavy-labeled tofacitinib ( 15N2-tofacitinib ) also evaluate .</brief_summary>
	<brief_title>TD-3504 SAD Healthy Subjects Subjects With Ulcerative Colitis ( UC )</brief_title>
	<detailed_description />
	<mesh_term>Ulcer</mesh_term>
	<mesh_term>Colitis , Ulcerative</mesh_term>
	<mesh_term>Colitis</mesh_term>
	<mesh_term>Tofacitinib</mesh_term>
	<criteria>Male female 18 55 year old Male subject must abstain sexual intercourse use highly effective method birth control Women child bear potential must negative pregnancy test either abstain sex use highly effective method birth control Body Mass Index ( BMI ) 18 32 kg/m2 Willing able give inform consent Additional inclusion criterion apply Inclusion Criteria Ulcerative Colitis ( UC ) subject : Subject history UC Subject either take medication UC take stable dose ulcerative colitis medication â‰¥ 14 day Additional inclusion criterion apply Is positive hepatitis A , B C , HIV tuberculosis Has clinically significant abnormality baseline laboratory evaluation Subject clinically significant abnormal electrocardiogram ( ECG ) Participated another clinical trial investigational drug ( medical device ) within 30 day prior screen ( within 60 day prior screen investigational drug biologic , currently participate another trial investigational drug ( medical device ) Additional exclusion criterion apply Exclusion Criteria Healthy Subjects : Use prescription drug chronic counter medication within 14 day prior clinic admission require continue use study participation , exception hormonal contraceptive hormone replacement therapy standard daily multivitamin . Additional exclusion criterion apply</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>April 2017</verification_date>
	<keyword>Active Mild Ulcerative Colitis , Active Moderate Ulcerative Colitis , Healthy Subjects</keyword>
</DOC>